Want to see RXST full AI Analyst Report?
RXST Stock Chart & Stats
$5.19
$0.28(5.49%)
At close: 4:00 PM EDT
$5.19
$0.28(5.49%)
Day’s Range― - ―
52-Week Range$4.48 - $13.22
Previous CloseN/A
Volume112.75K
Average Volume (3M)1.34M
Market Cap
$259.96M
Enterprise Value$1.77
Total Cash (Recent Filing)$208.80M
Total Debt (Recent Filing)$10.58M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 11, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding41,593,258
10 Day Avg. Volume1,325,215
30 Day Avg. Volume1,336,033
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.56
Price to Sales (P/S)3.19
P/FCF Ratio-22.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.79Price Target Upside50.05% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$147.25M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~77% TTM gross margin reflects strong unit economics of the Light Adjustable Lens platform. High product-level margins create durable profit potential as volumes scale, enabling the company to invest in commercial expansion and R&D while absorbing SG&A leverage if utilization improves.
Strategic Alcon CollaborationThe Alcon partnership is a structural growth catalyst: RxSight will develop, manufacture and supply collaboration products while Alcon leads global commercialization. Upfront/milestone payments and royalty potential materially de‑risk cash flow and extend distribution reach long term.
Installed Base & Consumable ModelA growing installed base of LDDs creates recurring, procedure‑driven consumable revenue as more surgeons adopt LALs. Capital placements seed long‑term demand for per‑patient lenses, providing a predictable revenue tail and margin leverage as utilization and repeat procedure rates rise.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow means the business is not yet self‑funding. Continued burn increases dependence on external financing or milestone payments (e.g., Alcon) and constrains the ability to sustainably scale sales and absorb commercialization costs if core demand stays weak.
Declining Core Product Sales & VolumesMaterial YoY declines in core product sales and LAL volumes signal adoption and utilization headwinds. Lower procedure throughput undermines the recurring consumable revenue model, slows scale benefits, and increases pressure on operating leverage and inventory flow‑through over the medium term.
Guidance Withdrawal & Strategic UncertaintyWithdrawing guidance while conducting a strategic review and undergoing leadership transition creates execution and visibility risk. Strategic shifts could delay commercial initiatives and resource allocation, complicating near‑term planning and investor certainty about the pace of adoption and profitability.
RxSight News
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $4.48 and its highest was $13.22 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $259.96M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Aug 05, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.329 by $0.039.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.29.
How many shares outstanding does RxSight have?
RxSight has 41,593,258 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.329. Following the earnings report the stock price went down -3.339%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.79 (50.05% Upside)
$7.79 (50.05% Upside)
Blogger Sentiment
Neutral
RXST Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 148.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.14%
Trailing 12-Months
Company Description
RxSight
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
RXST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call mixed notable strategic and clinical positives — most prominently the Alcon collaboration, solid clinical evidence, a healthy cash position (plus post-quarter $60M upfront), and new commercial leadership with plans to expand the sales force — alongside material near-term operational and financial challenges: a 19% decline in product sales, a 9% drop in LAL volumes, gross margin pressure from inventory, a reported net loss, and the withdrawal of full‑year guidance while management completes an assessment. Management presented a concrete action plan and resources to address utilization and execution, but near-term execution risk and competitive trialing remain.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$7.79
▲(50.05% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Butterfly Network
―
NeuroPace
―
Ceribell, Inc.
―
Ownership Overview
6.33% Insiders
15.38% Mutual Funds
14.90% Other Institutional Investors
49.73% Public Companies and
Individual Investors